Catalyst Pharmaceuticals, Inc.
Florida
United States
375 articles about Catalyst Pharmaceuticals, Inc.
-
Catalyst Pharmaceuticals Reports that the FDA Marketing Approval Previously Granted for Ruzurgi® is No Longer Valid
2/3/2022
Catalyst Pharmaceuticals, Inc. today reported that the District Court which heard Catalyst's Lawsuit against the FDA has entered summary judgment in favor of Catalyst.
-
Catalyst Pharmaceuticals to Participate in January 2022 Virtual Investor Conferences
1/4/2022
Catalyst Pharmaceuticals, Inc. announced that Patrick J. McEnany, Catalyst's Chairman and Chief Executive Officer and Steven Miller, Ph.D., Chief Scientific Officer/COO, will participate in two upcoming investor conferences.
-
Clinical Catch-Up: December 6-10
12/13/2021
There were a lot of clinical trial announcements this week, driven by the European Society for Medical Oncology annual conference. Here’s a look. -
Catalyst Pharmaceuticals Announces DyDo Pharma Initiation of a Phase 3 Study for FIRDAPSE® (amifampridine) in Japan
12/6/2021
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases, today announced that its collaboration partner DyDo Pharma ("DyDo") has initiated a Phase 3 registrational study in Japan to evaluate the efficacy and safety of Catalyst's FIRDAPSE®.
-
Catalyst Pharmaceuticals to Participate at the Piper Sandler 33rd Annual Virtual Healthcare Conference
11/15/2021
Catalyst Pharmaceuticals, Inc. announced that Patrick J. McEnany, Catalyst's Chief Executive Officer and Steven Miller, Ph.D., Chief Scientific Officer/COO, will participate at the Piper Sandler 33rd Annual Virtual Healthcare Conference being held on November 29, 2021 through December 2, 2021.
-
Catalyst Pharmaceuticals Reports Third Quarter 2021 Financial Results
11/9/2021
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases, today reported financial results for the third quarter ended September 30, 2021, and provided a corporate update.
-
Catalyst Pharmaceuticals to Report Third Quarter 2021 Financial Results on November 9, 2021The Company will host a Conference Call and Webcast on November 10, 2021, at 8:30 AM EST
10/25/2021
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), today announced that it will release its third quarter 2021 financial results after market close on Tuesday, November 9, 2021.
-
Catalyst Pharmaceuticals Receives Positive Decision from Appeals Court That Supports Orphan Drug Exclusivity for Firdapse® for LEMS
9/30/2021
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), today reported that it has received a positive decision from the 11th Circuit Court of Appeals in its appeal to overturn a District Court decision upholding the U.S. Food and Drug Administration’s (FDA) approval of another amifampridine product, Ruzurgi®
-
Catalyst Pharmaceuticals to Participate at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
9/17/2021
Catalyst Pharmaceuticals, Inc. today announced that Patrick J. McEnany, Catalyst’s Chief Executive Officer and Steven Miller, Ph.D., Chief Scientific Officer /COO, will participate at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
-
Catalyst Pharmaceuticals to Participate in Two Upcoming Investor Conferences in September 2021
9/10/2021
Catalyst Pharmaceuticals, Inc. announced that Patrick J. McEnany, Catalyst’s Chief Executive Officer and Steven Miller, Ph.D., Chief Scientific Officer /COO, will participate in two upcoming investor conferences:.
-
Catalyst Pharmaceuticals Appoints Mary Coleman as Vice President, Head of Investor Relations
8/16/2021
Catalyst Pharmaceuticals, Inc. today announced that Mary Coleman has been appointed to the newly created position of Vice President, Head of Investor Relations.
-
Catalyst Pharmaceuticals Announces Second Quarter 2021 Financial Results and Provides Corporate Update
8/9/2021
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases, today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update.
-
Catalyst Pharmaceuticals to Hold Second Quarter 2021 Financial Results and Corporate Update Conference Call and Webcast on Tuesday, August 10th, 2021
7/26/2021
Catalyst Pharmaceuticals, Inc. today announced that it will release second quarter 2021 financial results after market close on Monday, August 9, 2021.
-
Catalyst Pharmaceuticals Announces Issuance of U.S. Patent 11,060,128 a Method of Use Patent with Claims Covering Firdapse®
7/19/2021
New patent bolsters intellectual property protection for Firdapse® First in a family of four pending patents for Firdapse® to issue
-
BioSpace Movers & Shakers, July 9
7/9/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
BioSpace Movers & Shakers, July 2
7/2/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Catalyst Pharmaceuticals Appoints Pharmaceutical Executive Molly Harper to its Board of Directors
6/29/2021
Catalyst Pharmaceuticals, Inc. today announced the appointment of Molly Harper to the Company’s Board of Directors.
-
Catalyst Pharmaceuticals Announces Exclusive License and Supply Agreement with DyDo Pharma for the Development and Commercialization of Firdapse® in Japan
6/28/2021
Catalyst Pharmaceuticals, Inc. today announced that it has entered into an exclusive license and supply agreement with DyDo Pharma, Inc. (“DyDo Pharma”) for the development and commercialization of Firdapse.
-
Catalyst Pharmaceuticals, Inc.'s and KYE Pharmaceuticals' Lawsuit in Canadian Federal Court Quashes the Notice of Compliance (NOC) for Ruzurgi
6/3/2021
Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), and KYE Pharmaceuticals Inc. ("KYE"), today announced a positive decision in their lawsuit in Canadian Federal Court challenging Health Canada's approval of Medunik's New Drug Submission (NDS) for Ruzurgi®.
-
Catalyst Pharmaceuticals to Participate in Two Upcoming Investor Conferences
5/19/2021
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases, today announced that Patrick J. McEnany, Catalyst’s Chief Executive Officer and Steven Miller, Ph.D. Chief Scientific Officer /COO, will participate in two upcoming investor conferences: